Jinjin Zhang

Jinjin Zhang is a Principal Investigator at Arcus Biosciences since October 2022, previously serving as a Senior Research Scientist and Research Scientist at Gilead Sciences from October 2017 to October 2022, where contributions were made in protein chemistry for various drug discovery projects. Prior roles include Senior Scientist at NewLink Genetics, where Jinjin Zhang led a vaccine development study for the Zika virus and worked on innovative vaccine projects for Influenza and Ebola, and Postdoctoral Researcher at the Eunice Kennedy Shriver National Institute of Child Health and Human Development, focusing on glutamate receptor ion channel GluK2's structure and electrophysiology. Jinjin Zhang earned a Ph.D. in Biochemistry from The Ohio State University from 2004 to 2009.